Loading quotes...

Forecast

Buy	11
Hold	20
Sell	1

News Go to news feed

Perrigo unveils realignment and targets €80–100 million in cost savings

At the Canaccord growth conference Perrigo presented a 3‑S plan (stabilize, simplify, strengthen) to accelerate its turnaround, including portfolio simplification and a focus on category-led innovation. Management expects annual savings of €80–100 million, about 80% of which are planned for 2026, and a rebound in demand in the second half of 2026. E‑commerce is growing significantly faster than brick-and-mortar retail and should drive market share gains; strategic reviews cover infant nutrition and oral care, and disposals to reduce debt are possible. Perrigo stresses that implementing the measures and improving trade relationships with partners such as Walmart, Dollar General and Amazon should lay the foundation for long-term growth. » More on de.investing.com
Perrigo stock jumps 24% after surprise Q2 EPS beat

Perrigo reported adjusted diluted EPS of $0.50 for Q2 2026 (consensus $0.34) and adjusted core EPS of $0.46 on revenue of about $1.02 billion, sending the stock up roughly 24%. The unexpectedly strong result was attributed to aggressive cost cuts and operational discipline under the “Three‑S” strategy, although core net sales declined about 3.1%. The sale of the dermocosmetics unit generated approximately €305.6 million and will be used to reduce debt; management reiterated full‑year guidance of adjusted total EPS of $2.00–$2.30 and adjusted core EPS of $2.25–$2.55. » More on de.investing.com
Perrigo approves quarterly dividend of $0.29

Perrigo's board of directors has approved a quarterly dividend of $0.29 per share, payable on September 15, 2026 to shareholders of record on August 28, 2026. On an annual basis this corresponds to $1.16 per share. Perrigo markets over-the-counter self-medication products primarily in North America and Europe. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Perrigo Company has already paid €0.75 in dividends. The last payout was in September.

Financials

In the last quarter, Perrigo Company had revenue of €896.19m and net profit of €65.19m

(EUR)	June 2026	YoY
Revenue	896.19m	0.57%
Gross profit	275.39m	11.07%
Net profit	65.19m	1,009.49%
EBITDA	191.45m	45.50%

Fundamentals

Metric	Value
Market capitalization	€2.04bn
Number of shares	138.77m
52-week high/low	€16.14 - €8.32
Dividend yield	7.16%
Dividends TTM	€1.00
Beta	0.54
P/E ratio	-1.24
PEG ratio	0.00
P/B ratio	0.90
P/S ratio	0.54

Company profile

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.